RxDoctor Payments Data
★ My doctorsLook up a doctor →

Gary Symkoviak

Cardiovascular Disease · Murray, UTNPI 1841273844

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,680 and has fallen 76.3% since, to $398 in 2021.

$3,290in general payments, 2019–2025

Across 185 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$726
  • Amgen$630
  • Amarin Pharma, Inc.$335
  • Boston Scientific$329
  • Johnson & Johnson$279
  • Sanofi-aventis U.S. LLC$164
  • plus $828 from 13 others

What the payments were for

  • Food & beverage$3,26699%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer39$726
Amgen29$630
Amarin Pharma, Inc.16$335
Boston Scientific21$329
Johnson & Johnson16$279
Sanofi-aventis U.S. LLC14$164
E.r. Squibb & Sons, L.L.C.11$154
Lundbeck LLC7$153
Boehringer Ingelheim6$106
Novartis6$87
Esperion Therapeutics, Inc.5$79
Arbor Pharmaceuticals, Inc.3$44
Medicure Pharma Inc.1$40
Gilead2$34
Regeneron Healthcare Solutions, Inc.2$33
Merck2$31
Kowa Pharmaceuticals America, Inc.2$29
AstraZeneca2$23
Aegerion Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,290 in reported general payments places this provider in the 65th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah →

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$7,612
BrilintaTicagrelor11$4,821
Losartan Potassium11$196
Atorvastatin Calcium18$162
Amlodipine Besylate11$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$726$7,61213 claims
AstraZenecaBrilinta$23$4,82111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Murray

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →